- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Overview of Available Third-Line Options in mCRC
Panelists discuss how available third-line therapies, such as FTD/TPI, regorafenib, and others, are chosen based on survival data, safety, and patient quality of life.
EP: 1.Overview of Available Third-Line Options in mCRC
EP: 2.Evidence Supporting FTD/TPI ± Bevacizumab in mCRC
EP: 3.Efficacy of Fruquintinib and Comparisons Across Agents in mCRC
EP: 4.Selecting Among Third-Line Therapies in Clinical Practice for mCRC
EP: 5.Leveraging Real-World Evidence in Sequencing Decisions for mCRC
EP: 6.Translating Real-World Outcomes in mCRC Into Patient Conversations
EP: 7.Incorporating Patient-Reported Outcomes in mCRC Into Shared Decision-Making
EP: 8.Real-World Evidence in mCRC: Special Populations and Safety Assessment
EP: 9.Defining Future Needs for Real-World Evidence in mCRC
EP: 10.Applying Third-Line Therapy in mCRC: Community vs Academic Settings
Panelists discuss the therapeutic landscape for metastatic colorectal cancer once patients progress to third-line treatment. They outline the available agents, including trifluridine/tipiracil (FTD/TPI), regorafenib, and newer targeted therapies, emphasizing how trial data inform their integration into practice.
The RECOURSE trial plays a central role in establishing FTD/TPI as a viable option, with its demonstrated improvements in overall survival and a manageable safety profile. Clinicians highlight how such data provide confidence in recommending therapy beyond standard second-line regimens.
Ultimately, they stress that treatment choice must balance efficacy with tolerability to ensure quality of life for patients already heavily pretreated.
